Survivin is a new member of the inhibitor of apoptosis protein ( IAP ) family that is implicated in the control of cell proliferation and the regulation of cell life span. This protein is selectively expressed in most human carcinomas but not in normal adult tissues. To down -regulate a human survivin expression as a strategy for cancer gene therapy, we designed two hammerhead ribozymes ( RZ -1, RZ -2 ) targeting human survivin mRNA. RZ -1 and RZ -2 efficiently cleaved the human survivin mRNA at nucleotide positions + 279 and + 289, which was identified by in vitro cleavage assay using in vitro transcribed ribozymes and truncated survivin mRNA substrate. To investigate the function of the ribozymes in cells, the sequences of the ribozymes were cloned into replication -deficient adenoviral vector and transferred to breast cancer cell, MCF -7. The infection with adenovirus encoding the ribozymes resulted in a significant reduction of survivin mRNA ( 74% and 73%, respectively ) and protein. As revealed by nuclear condensation / fragmentation and flow cytometry analysis, inhibition of survivin gene by ribozymes increased apoptosis and sensitivity induced by etoposide or serum starvation. Our results suggest that the designed hammerhead ribozymes against survivin mRNA are good candidates for feasible gene therapy in the treatment of cancer.
A poptosis plays a pivotal role in regulating tissue development and homeostasis in multicellular organisms. It also provides essential protective mechanism against the development of neoplasia by removing cells with damaged DNA. 1, 2 This is an extremely well -organized process involved with DNA fragmentation into a nucleosomal ladder, chromatin condensation, membrane blebbing, cell shrinkage, and disassembly into membrane -enclosed vesicles. Aberrations of this process participate in human disease and may contribute to cancer development by abnormally prolonging cell viability with accumulation of transforming mutations. 3 Apoptosis is mediated by caspase family proteins, which are present as proenzymes in viable cells and are proteolytically processed to generate active forms in apoptotic cells. The counteraction of caspases by apoptosis inhibitory proteins is crucial in the regulation of apoptosis. Among the regulators of apoptotic pathways, Bcl -2 proteins have been implicated in the control of mitochondrial homeostasis, most notably cytochrome C release. 4 In addition to Bcl -2 family, the inhibitor of apoptosis protein (IAP ) family has recently attracted attention for its broad distribution and evolutional conservation. 5, 6 IAPs were identified originally as a sequence of approximately 70 amino acids that was tandemly repeated in a class of baculovirus proteins blocking apoptosis induced during baculovirus infection. 7, 8 IAPs have baculovirus IAP repeat (BIR ), a caspase recruitment domain ( CARD ), a RING finger, and an ubiquitin-conjugating domain nucleotide -binding P -loop motif.
Survivin is a structurally unique member of the IAP family that contains a single BIR and no C -terminal RING finger motif. It is involved in both control of cell division and inhibition of apoptosis. 9 Specifically, its antiapoptotic function is related to the ability to inhibit caspases directly or indirectly. Survivin shows markedly different tissue expression when compared with other IAPs. 9 It is expressed during fetal development in human, but is not detected in most terminally differentiated normal adult tissues with only a few exceptions. 10 -12 Survivin is also overexpressed in most human cancers including carcinoma of the lung, 13 breast, 14 colon, 15 stomach, 16 esophagus, 17 pancreas, 18 bladder, 19 uterus, 20 ovaries, 21 large cell non Hodgkin's lymphoma, 22 leukemia, 23, 24 neuroblastoma, 25, 26 melanoma, 27 and nonmelanoma skin cancers. 28 Survivin is expressed in the G2 / M phase of the cell cycle. It associates with microtubules of the mitotic spindle at the beginning of mitosis and, if these interactions are disrupted, survivin loses its antiapoptotic function. Survivin may, thus, counteract a default induction of apoptosis in G2 / M phase and the overexpression in cancer may overcome this apoptotic checkpoint, favoring aberrant progression of transformed cells through mitosis. Overexpression of survivin in most human tumors -but not in normal adult tissues -has made survivin a promising therapeutic target for anticancer therapies.
Ribozymes are a powerful new therapeutic tool to diminish or eradicate RNA molecules from cells. 29 Among several ribozymes, the hammerhead ribozyme is the simplest and best characterized. The hammerhead ribozyme is an RNA -based enzyme that binds to and cleaves RNA molecules in a sequence -specific manner. The hammerhead ribozyme consists of a catalytic domain and a flanking antisense section. 30 The hammerhead ribozyme cleaves after NUX ( N can be any nucleotide, X can be any nucleotide except G ) sequence of target mRNA and the antisense sequence of the ribozyme functions in the specific recognition of target site. Compared with antisense RNA, binding of ribozyme to its target mRNA is more stringent and reduces nonspecific effects often associated with antisense approaches. 31, 32 Therefore, it is being increasingly considered and used as gene therapeutic agent for human malignancies. 33, 34 In the present study, as an alternative strategy for survivin inhibition, we designed two hammerhead ribozymes against human survivin mRNA and examined the function of the ribozymes and the effects of developing the ribozymes as a tool of cancer gene therapy on the antiapoptosis of survivin in MCF -7 cells.
Materials and methods

Selection of ribozymes against human survivin mRNA
Based on the analysis of primary and secondary structure of the human survivin mRNA, optimum target sites for each hammerhead ribozyme were investigated. We selected target sequences that are surrounding NUX triplets within the single-stranded regions and lack any substantial homology with human nonsurvivin sequences in GenBank database.
Synthesis of ribozymes and substrate RNA with T7 RNA polymerase
Oligodeoxynucleotides corresponding to the wild -type ribozymes as well as mutant ribozymes were synthesized and purified. The pcDNA3.1( + ) plasmid ( Invitrogen, San Diego, CA ) was digested with EcoRI and each oligonucleotide was subcloned into the vector through EcoRI cloning site ( pcDNA3.1( + )/RZ ). The human survivin mRNA fragment from + 15 to + 759 was used as the substrate for ribozyme -catalyzed cleavage reaction. cDNA template spanning the human survivin mRNA was generated by RT-PCR from the total RNA of MCF-7 cells with appropriate primers ( forward: 5 0 -CAGATTTGAATCGCGG GAC -3 0 , reverse: 5 0 -ATGACCTCCAGAGGTTTC -3 0 ) and then cloned into the pGEM -T easy vector ( Promega, Madison, WI) to generate pGEM -Teasy /survivin. To generate the mRNA substrate corresponding to bcl -2 for the substrate specificity of ribozyme, the cDNA was amplified using bcl -2 -specific primers ( forward: 5 0 -GCT-TTTCCTCTGGGAAGGAT-3 0 , reverse: 5 0 -CCTCCGTTA-TCCTGGA TCCA -3 0 ) and subcloned into pGEM -Teasy vector. The radiolabeled RNA substrate and each ribozyme RNA were prepared by T7 RNA polymerase -directed in vitro transcription using Megascript Kit ( Ambion, Beverly, MA ). Briefly, 1 g of SmaI-linearized pGEM -Teasy /survivin and EcoRV-linearized pcDNA3.1( + )/ RZ were incubated separately in 20 L of transcription buffer containing 40 mM Tris -HCl, pH 7.5, 6 mM MgCl 2 , 20 mM dithiothreitol, 5 mM NTPs, 40 U of RNase inhibitor, and 10 U of T7 RNA polymerase. For the synthesis of radiolabeled substrate RNA, 50 Ci of [ a-
32 P ]CTP ( NEN Life Sciences, Boston, MA ) was added instead of CTP. The reaction was carried out at 378C for 5 hours, and followed by the digestion with 2 U of RNase -free DNase I at 378C for 30 minutes. RNA was purified and the free nucleotides were removed using the Qiaquick nucleotide removal kit ( Qiagen, Hilden, Germany ). The RNA was checked by UV absorption and stored frozen at À 708C.
In vitro cleavage of survivin RNA by the ribozyme
In vitro cleavage reactions were performed as previously described. 35 Briefly, the radiolabeled mRNA substrates and ribozymes were separately preincubated at 378C for 3 minutes in 50 mM Tris -HCl ( pH 7.5) and 1 mM EDTA. Each mixture was then brought to 10 mM MgCl 2 and mixed together to initiate the cleavage reaction at 378C. The reaction products were suspended at an equal volume of RNA gel loading buffer (95% formamide, 0.025% xylene cyanol, 0.025% bromophenol blue, 18 mM EDTA, 0.025% SDS ) and the tube was heated at 958C for 5 minutes and quickly cooled on ice. The reaction mixture was resolved by electrophoresis in 4% polyacrylamide -8 M urea gel at 150 V for 2 hours. The gel was dried and exposed to film for autoradiography. The percentage of cleavage was quantified by PhosphorImager ( FujiFilm, BAS -1500) analysis of the radiolabeled bands after subtracting background values.
Construction of recombinant adenovirus -encoding ribozymes
In order to produce recombinant adenovirus -encoding wild and mutant ribozymes, we used the Adeno-X 2 expression system ( Clontech, Palo Alto, CA ). A DNA fragment encoding ribozyme, obtained by the digestion of pcDNA3.1( + ) / RZ with NdeI and NotI, was subcloned into the pShuttle vector. The ribozyme expression cassette, provided by double digestion of recombinant pShuttle vector with PI -SceI/ I-CeuI, was inserted into Adeno-X 2 viral DNA to generate recombinant adenoviruses, designated Ad -RZs ( Ad -RZ -1, Ad -RZ -2, or Ad -mut, respectively ). Next, each recombinant adenovirus was digested with PacI and then transfected to HEK293 cells by Lipofectamine plus reagent ( Invitrogen, Carlsbad, CA ). Recombinant adenovirus was then plaqueamplified three to five times and high -titer virus stocks were prepared by infecting HEK293 cells, purified by two -step CsCl gradient centrifugation. The viral titer was determined by observation of plaque formation on an agar medium. Optimal multiplicity of infection ( MOI ) was determined to achieve an optimal balance of high gene expression and low viral titer to minimize cytotoxicity.
Infection of cells
MCF -7 cells expressing high level of survivin were obtained from the American Type Culture Collection (Manassas, VA ) and cultured in RPMI medium containing serum as recommended by the supplier. To measure the ability of adenovirus to infect the MCF -7, the Ad -lacZ encoding b -galactosidase was used at various titers to cells. After 72 hours, infected cells were fixed in 0.3% glutaraldehyde in PBS, stained with X -gal, and counted under Â200 magnification.
Analysis of ribozyme expression in cells
Subconfluent cultures of MCF-7 were incubated with each type of adenovirus at an MOI of 50 for 24 hours at 378C. Total RNA was isolated from the infected cells using Trizol reagent (Life Technologies, Grand Island, NY ) and treated with RNase -free DNase I (Promega). The expression of the ribozyme in MCF -7 cells was examined by RT-PCR using the primers, forward: T7 primer ( 5 0 -ATACGACTCACT-ATAGGGCGA -3 0 ) and reverse: ribozyme -specific primer
and reverse: 5 0 -CTCCTTAATGTCACGCACGATTT C -3 0 primers were used.
Northern blot analysis
Twenty micrograms of total RNA was loaded on 1% agarose /formaldehyde gel, electrophoresed, and then mounted on a nylon membrane by capillary transfer. A survivinspecific single -strand probe was generated by asymmetric PCR of a 750-nt fragment of the survivin cDNA generated by digestion of pGEM -Teasy /survivin with SmaI. The purified fragment was mixed with 15 pmol of dNTP and 25 Ci of [ a -32 P ] dCTP (NEN Life Sciences ) in 20 mM Tris -HCl, 50 mM KCl, pH 8.4, 1.5 M MgCl 2 , containing 0.2 g/L survivin forward primer (5 0 -GCACTTTCTTCG-CAGTTTCC -3 0 ) and 2.5 U of Ex Taq DNA polymerase ( TaKaRa Biotech, Shiga, Japan ). Amplification was carried out with 34 cycles of denaturation at 948C for 30 seconds, annealing at 608C for 30 seconds, and extension at 728C for 1 minute. After purification, the survivin probes were heated at 1008C for 5 minutes and immediately added to hybridization reaction.
Western blot analysis
Adenovirus-infected cells were washed twice with cold PBS, lysed for 30 minutes on ice in RIPA buffer (150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P -40, 0.1% SDS, 50 mM Tris -HCl, pH 8.0) supplemented with fresh protease inhibitor cocktails ( Sigma, St. Louis, MO ). After centrifugation at 14,000Âg at 48C for 30 minutes, the supernatant was harvested and protein concentrations were determined with a Bio -Rad protein assay ( modified Lowry assay, Hercules, CA ). Thirty micrograms of protein was loaded on a 12% polyacrylamide gel. Following electrophoretic separation, the proteins were transferred to nitrocellulose membrane (Life Technologies, Gaithersburg, MD ). After blocking, membrane was incubated with goat antisurvivin or goat antiactin antibody (Santa Cruz Biotechnology, Santa Cruz, CA ). The membrane was washed twice and then incubated with a horseradish peroxidase -conjugated antigoat antibody (Santa Cruz Biotechnology ). The signals were visualized using ECL -Plus enhanced chemiluminescence ( Santa Cruz Biotechnology ).
Apoptosis analysis
For 4,6 -diamidino -2 -phenylindole (DAPI ) staining, MCF -7 cells were infected with recombinant adenovirus at an MOI of 50 at 378C for 72 hours. Cells were fixed with 0.3% glutaraldehyde in PBS for 5 minutes and stained with DAPI ( 0.5 g /mL in PBS /0.1% Nonidet P -40) for 15 minutes. After washing with PBS, 80% glycerol was added to each Figure 1 Sequence and structure of two human survivin -specific hammerhead ribozymes and cleavage products of two ribozymes. A: Sequence and predicted secondary structure of RZ -1 and RZ -2, the complementary mRNA sequence, and expected cleavage sites ( indicated by arrow ) are shown. Base substitutions at G!A, A!C in RZ -1 generate catalytically inactive mutant RZ -1 ( mut RZ -1 ). B: Cleavage products of two ribozymes. The numbers indicate the sizes of cleavage products when the 805 -nt -long survivin mRNA fragment was used as substrate.
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Hammerhead ribozymes for survivin KS Choi et al well and photographed using fluorescent microscope ( Carl Zeiss, Göttingen, Germany ). For flow cytometry analysis, cell suspension was prepared using the CycleTEST 2 PLUS DNA Reagent Kit (Becton Dickinson, San Jose, CA ) following manufacturer's instructions and stained with propidium iodide (PI ). Briefly, after infection with each recombinant adenovirus for 72 hours, cells were treated with complete medium, serum -free medium, or etoposide (50 M ) for 24 hours. Cells were harvested and resuspended in 1Â binding buffer. Trypsin buffer (250 L ) was added and, 10 minutes later, trypsin inhibitor and RNase buffer ( 200 L ) were added. After 10 minutes, PI stain solution ( 200 L ) was added. The tube was then incubated for 10 minutes in the dark on ice and analyzed using a FACS vantage (Becton Dickinson) within 3 hours after addition of PI stain solution. DNA histograms were analyzed using the CELL QUEST software to evaluate cell cycle compartments, and cells containing a sub -G1 DNA content were defined as apoptotic cells.
Results
Design of the human survivin -specific hammerhead ribozymes
As RNA contains extensive secondary structures and is often bound with proteins, assessable sites for ribozyme cleavage may be restricted in target RNA molecules. To provide the highest accessibility of the ribozyme to the human survivin mRNA, we examined the potential secondary structure of the human survivin mRNA sequence through the energy minimization approach. Based on the computer search for the single-stranded region with NUX triplets, we selected two ribozymes, which are designated RZ -1 and RZ -2. RZ -1 lanes 1 -4 ) , and substrate specificity of RZ -1 and RZ -2 on 598 -nt -long bcl -2 mRNA fragment ( lanes 5 and 6 ). Each reaction was carried out at 378C for 60 minutes. and RZ -2 cleave the human survivin mRNA at positions + 279 and +289, respectively. The sequence and structure of RZ -1 and RZ -2 are shown in Figure 1A . Cleavage sites of these ribozymes are also indicated with arrow in Figure 1 , A and B. Search of GenBank for the binding region of RZ -1 and RZ -2 indicated that there was no significant homology between the regions of the survivin mRNA bound by the ribozymes and any known human nonsurvivin mRNA. It has been established that substitution of two bases at the catalytic core of the hammerhead ribozyme led to an almost total loss of catalytic activity. 36 We also designed mutant ribozyme with two substitutions in RZ -1, designated as mut RZ -1. These ribozymes were then tested for their catalytic activities in vitro.
Catalytic cleavage of the human survivin mRNA by RZ -1 and RZ -2
Ribozymes were synthesized by in vitro transcription of the corresponding recombinant plasmids, and their catalytic activities and specificities were examined using the 32 P -labeled RNA substrates. For human survivin gene, 805 -nt mRNA containing the expected cleavage sites of the 
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Hammerhead ribozymes for survivin KS Choi et al ribozymes was used as substrate. Electrophoretic autoradiograms of the cleavage reaction catalyzed by RZ -1 and RZ -2 are displayed in Figure 2 . The results showed that both RZ -1 and RZ -2 cleaved the survivin mRNA substrate in a highly sequence -specific fashion. RZ -1 produced two cleavage products of the expected sizes ( 327 and 478 nt ) from the 805 -nt -long survivin mRNA substrate (Fig 2A ) . Similarly, the same substrate was cleaved by RZ -2 to yield 337 -and 468 -nt -long reaction products ( Fig 2B ) . The time course of cleavage reaction showed RZ -1 and RZ -2 to have almost the same activities in cleavage catalysis, although the cleavage rate of RZ -2 is higher than that of RZ -1 within 30 minutes (Fig 2C ) . At equimolar ratio of substrate to ribozyme, RZ -1 and RZ -2 cleaved 86% and 87% of the mRNA at 378C in 1 hour, respectively. In contrast, mutant ribozyme with two base substitutions within catalytic core of RZ -1 abolished its enzymatic activity (Fig 2D ) . Additionally, in order to examine the specificity of these ribozymes, bcl -2 mRNA fragment was used as RNA substrate. RZ -1 and RZ -2 did not show any significant endonuclease activity on bcl -2 mRNA ( Fig 2D ) . Collectively, these results demonstrate that the designed ribozymes have high catalytic activity and substrate specificity. Next, the cleavage reaction was carried out in the presence of Mg 2 + concentrations ranging between 0 and 10 mM. As shown in Figure 3 , reaction did not occur in the absence of MgCl 2 , but the cleavage rate was greatly increased with elevation of Mg 2 + concentrations, indicating that Mg 2 + is required for ribozyme -mediated survivin mRNA cleavage.
Expression of the survivin ribozyme in MCF -7 cells
The MCF -7 cell line expressing high levels of survivin mRNA was selected as target cell to investigate the effect of the ribozymes. In order to introduce ribozymes in MCF -7 cells, different types of replication -deficient adenovirus encoding the ribozymes under cytomegalovirus early promoter were constructed and designated as Ad -RZ -1, Ad -RZ -2, and Ad -mut, respectively. The infection efficiency was determined by infecting MCF -7 cells with the adenovirus -encoding galactosidase, Ad -lacZ. More than 90% of cell populations were X -gal -positive at an MOI of 50 after 72 hours of infection. Thus, the MCF-7 cells were infected with Ad -RZ -1, Ad -RZ -2, or Ad -mut under the same conditions. After 72 hours of infection, RT-PCR was performed with ribozyme -specific primers to confirm the 
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Hammerhead ribozymes for survivin KS Choi et al expression of ribozymes in cells (Fig 4A ) . As shown in Figure 4B , PCR fragment of expected size was detected in Ad -RZ -1, Ad -RZ -2, or Ad -mut, but not in mock adenovirus (Ad ). These results verified that Ad -RZ -1 and Ad -RZ -2 successfully expressed survivin -specific ribozymes in MCF -7 cells.
Decrease of human survivin mRNA and protein in MCF -7 cells by RZ -1 and RZ -2
In order to determine whether RZ -1 and RZ -2 caused an effect on the level of survivin mRNA in MCF -7 cells, we used Northern blot analysis from the cells infected with each of recombinant adenovirus. As shown in Figure 5A , both Ad -RZ -1 and Ad -RZ -2 caused significant decline in the level of survivin mRNA. Ad -RZ -1 and Ad -RZ -2 decreased 75% and 74% of survivin mRNA compared with Ad -mock, respectively. No difference was seen in human b -actin as internal control. Western blot analysis was performed to see the coincident reduction of survivin protein in recombinant adenovirus -infected cells. Figure 5B showed that both Ad -RZ -1 and Ad -RZ -2 also decreased the level of survivin protein, but Ad -mut did not. From these results, we concluded that the expression of either RZ -1 or RZ -2 can cause selective degradation of the human survivin mRNA, thereby reducing the survivin protein level in MCF -7 cells.
Induction of apoptosis in MCF-7 cells by RZ -1 and RZ -2
To analyze the biological effect associated with inhibition of survivin expression by ribozyme, we measured the apoptosis and sensitivity of recombinant adenovirus -infected MCF-7 cells to apoptotic stimuli, such as serum starvation or etoposide. Nuclear condensation was detected by the DAPI staining. At 3 days after infection with each type of recombinant adenovirus, MCF -7 cells were stained with DAPI. As shown in Figure 6A , Ad -RZ -1 and Ad -RZ -2 elicited about a 2-fold increase in the number of apoptotic cells compared to Ad or Ad -mut. To obtain more specific data about the percentage of apoptotic cells, a flow cytometry analysis was conducted. After 3 -day culture of MCF -7 cells infected with recombinant adenovirus, MCF-7 cells were treated with complete medium, serum -free medium, or etoposide ( 50 M) for 24 hours at 378C, respectively. As shown in Figure 6Ba , Ad -RZ -1-or Ad -RZ -2 -infected cells resulted in about a 2-fold increase of apoptotic cells, compared with Ad -and Ad -mut -infected cells. In addition to spontaneous apoptosis ( Fig 6, A and Ba ), Ad -RZ -1 increased the sensitivity of MCF -7 cells to serum starvation or chemotherapeutic agent, etoposide (50 M) . By the analysis of DNA content, Ad -RZ -1 revealed 2.5 -and 3.2 -fold increases in the fraction of apoptotic cells ( sub -G1 peak ) compared with Ad -and Ad -mut -infected cells (Fig 6Bb, c ) . Similar results were also shown in Ad -RZ -2-infected cells (Fig 6Bb, c ) .
Discussion
Survivin is expressed in a high proportion of most human cancers but not in terminally differentiated normal adult tissues. Thus, altered expression of survivin appears to define a common event associated with the pathogenesis of most human cancers. 9 The antagonists of survivin including antisense 37 -43 or dominant negative mutant 37, 41, 44, 45 were reported to elicit spontaneous apoptosis of cancer cells in vivo as well as in vitro and to enhance the sensitivity of chemotherapy in cancer cells. It was reported that transfection of both YUSAC -2 and LOX malignant melanoma cells with survivin antisense or dominant negative mutant ( Cys84Ala ) resulted in increased apoptosis in the absence of additional genotoxic stimuli. 27 Shankar et al 43 also reported that the administration of survivin antisense oligonucleotides ( SAOs ) to human neuroblastoma (MSN ) and oligodendroglioma ( TC620 ) resulted in a dose -dependent reduction in survivin protein. A phosphorylation -defective survivin mutant (Thr34Ala ) has been reported to trigger apoptosis in several human melanoma cell lines and to enhance the cell death induced by the chemotherapeutic drug, cisplatin, in vitro. Conditional expression of survivin mutant (Thr34Ala ) in YUSAC2 melanoma cells prevented tumor formation in subcutaneously injected CB.17 immunodeficient beige mice. 44 Replication -deficient adenovirus -encoding survivin mutant (Thr34Ala ) caused initiation of mitochondrial apoptotic pathway in various cancer cells and suppressed tumor growth in the xenograft breast cancer model. 45 In addition to antisense and dominant -negative mutant technology, there are alternative methods -ribozyme and RNA interference ( RNAi ) approach -to inhibit a specific gene expression. The RNAi is a powerful new tool for specific disruption of gene expression. 46 However, RNAi is not a proper method to down -regulate survivin gene expression because the coding strand of the survivin gene shows extensive complementarity to the EPR -1 gene.
Ribozymes are being increasingly considered for the potential application in the sequence-specific inhibition of gene expression. Ribozymes may be valuable therapeutic tools for repairing cellular RNA transcribed from mutated genes, or for destroying unwanted RNA transcripts in the cell. Thus, ribozymes have the potential to be developed as drugs or as tools to elucidate the function of gene. As therapeutics, ribozymes could be administered either by successive external application akin to chemotherapy, or by endogenous transcription in a gene therapy fashion. There are two approaches to deliver ribozyme to cells for the successful inhibition of gene expression. One is exogenous delivery of the presynthesized ribozyme to the cell directly. The other is endogenous delivery of ribozyme as a part of vector to the cell. Exogenous delivery requires stabilization of oligonucleotides against degradation by nucleases. Stabilization should not compromise catalytic activity of the ribozyme. Thus, the choice of derivative and its placement are crucial. Commonly used modifications are the fluoro, amino, allyl, and O -methyl derivatives at 2 positions. In general, poor uptake is a challenge for exogenous delivery of ribozymes to cells in culture. Endogenous delivery depends on efficient transfer of the gene -encoding ribozyme into the cells. To overcome this problem, DNA fragment corresponding to survivin -specific ribozyme is cloned into the adenoviral vector. The adenoviral vector is one of the most powerful vehicles for introducing genes into mamma-lian cells. Recombinant adenovirus can be used to transmit interesting gene to virtually all human and many nonhuman cell types. Adenovirus-mediated targeting for the regulators of cell cycle and apoptosis has been investigated for their potential suitability for cancer gene therapy, or to enhance the efficacy of chemotherapy.
In this study, we designed two hammerhead ribozymes targeting human survivin mRNA and investigated the function of the ribozymes in vitro and in the cells infected with the adenovirus -carrying ribozymes. We finally examined the possibility of in vivo application in cancer gene therapy. We selected two ribozymes, RZ -1 and RZ -2, that cleave human survivin mRNA at positions + 279 and + 289, respectively. GenBank search of the binding region of RZ -1 and RZ -2 indicated that there is no homology of two binding regions of the human survivin mRNA to any known human mRNA. RZ -1 and RZ -2 produced two cleavage products of the expected sizes from human survivin mRNA substrate, respectively (Fig 2, A and B ) . According to the time course of cleavage reaction, it appeared that RZ -1 and RZ -2 had almost the same cleavage activity, although cleavage rate of RZ -2 is higher than that of RZ -1 within 30 minutes ( Fig 2C ) . Kinetic analysis predicted that RZ -2 composed of 15 residue flanking sequences with 33% GÁC content has a higher turnover rate than RZ -1 consisting of relatively long arms ( 18 bp) with high GÁC content (56% ). The length and base composition of the antisense arms greatly contribute to the turnover rate of the ribozymes, thereby influencing its catalytic function. 47 -49 RZ -1 and RZ -2 cleaved 86% and 87% of the survivin mRNA at 378C in 1 hour, respectively, and did not show any significant endonuclease activity on bcl -2 mRNA ( Fig 2D ) . From these results, both ribozymes show a high degree of catalytic activity and substrate specificity. In order to deliver the ribozyme to MCF -7 cells, we constructed recombinant adenovirus expressing each type of ribozymes (Ad -RZ -1, Ad -RZ -2, Ad -mut ). Ad -RZ -1 and Ad -RZ -2 successfully expressed human survivin ribozyme in MCF -7 cells (Fig 4A ) . In order to test whether RZ -1 and RZ -2 are functional in MCF -7 cells, we determined the level of survivin mRNA and protein from the cells infected with recombinant adenovirus. As shown in Figure 4B , Ad -RZ -1 and Ad -RZ -2 all caused significant declines in the level of human survivin mRNA and protein.
In contrast, mutant ribozyme was not effective. From these results, we concluded that the expression of either RZ -1 or RZ -2 can cause selective degradation of the human survivin mRNA, thereby reducing the survivin protein level in MCF -7 cells. We then measured the apoptosis to analyze the biological effect associated with the inhibition of survivin mRNA by ribozymes. In addition to spontaneous apoptosis, infection with Ad -RZ -1 and Ad -RZ -2 increased the apoptosis of MCF -7 cells induced by serum starvation or etoposide ( Fig 6, A and B ) .
It is reported that there are three alternatively processed survivin transcripts, designated as survivin (regularly spliced form ), survivin -ÁEx3 (lacking exon 3 ), and survivin -2B ( retaining a part of intron 2 as a cryptic exon ). 50 These isoforms of survivin have different antiapoptotic properties. Survivin -ÁEx3 shows a largely preserved antiapoptotic function, whereas survivin -2B has a marked reduction of antiapoptotic potential. The presence of distinct isoforms of survivin that are expressed differentially suggests that survivin plays a complex role in regulating apoptosis. The cleavage site of RZ -1 is placed on the boundary of exons 2 and 3, whereas that of RZ -2 is placed within exon 3. Therefore, it is supposed that RZ -1 interacts with and cleaves only regularly spliced survivin, but RZ -2 interacts with survivin as well as survivin -2B.
In summary, we showed that suppression of survivin gene expression was achieved through the adenovirus -mediated ribozyme and thereby increased the apoptosis of MCF -7 cells. Further studies will be required to improve the efficiency of ribozyme and assess the relevance of survivin level to cell survival. These data suggest that adenovirusmediated ribozyme targeting human survivin mRNA may provide a potential novel tool for cancer gene therapy, selectively promoting cancer cell apoptosis and enhancing the efficacy of chemotherapeutic drugs, although it still requires in vivo trial.
